Association for Accessible Medicines
Association for Accessible Medicines Political Action Committee
Lobbying: all issues, rounded to the nearest $10,000. Two filers, same 21 months. This PAC gives money raised from the trade association’s employees or members; the trade association itself can’t give to campaigns from its treasury.
Spend by quarter Pro
Free account See ProWhat they lobby on
MethodAssociation for Accessible Medicines reported federal lobbying in 8 of the last 8 quarters (Q4 2024 to Q3 2026), with its own in-house lobbyists and 7 outside firms. What follows is what the filings say it lobbied on, not which way.
Issue areas ranked by quarters filedQ4 24 → Q3 26
- Copyright/Patent/Trademark8/8
- Health Issues8/8
- Labor Issues/Antitrust/Workplace8/8
- Medicare/Medicaid8/8
- Pharmacy8/8
Trade (domestic/foreign) 8 of 8 · Manufacturing 7 of 8 · 2 more · Show all 9
- Trade (domestic/foreign)8/8
- Manufacturing7/8
- Budget/Appropriations2/8
- Defense1/8
Bills named in the filings 55 bills, this period
- S. 1041 Affordable Prescriptions for Patients Act17 filings
- S. 1096 Preserve Access to Affordable Generics and Biosimilars Act14 filings
- S. 1040 Drug Competition Enhancement Act11 filings
- S. 43 / H.R. 6485 Skinny Labels, Big Savings Act8 filings
- H.R. 1843 To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.6 filings
50 more, 27 named in only one filing · Show all 55
- S. 1302 Increasing Transparency in Generic Drug Applications Act6 filings
- S. 1414 / H.R. 9661 Expedited Access to Biosimilars Act6 filings
- S. 1546 / H.R. 3152 Patent Eligibility Restoration Act of 20256 filings
- S. 1553 / H.R. 3160 PREVAIL Act6 filings
- S. 2276 / H.R. 3269 ETHIC Act6 filings
- H.R. 1051 To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes.5 filings
- S. 1954 / H.R. 5526 Biosimilar Red Tape Elimination Act5 filings
- S. 2027 / H.R. 4132 Prescription Information Modernization Act of 20255 filings
- H.R. 5811 Restoring America’s Leadership in Innovation Act of 20254 filings
- S. 1784 / H.R. 4191 MAPS Act4 filings
- S. 1891 / H.R. 1396 PILLS Act4 filings
- S. 3469 BIOSECURE Act of 20254 filings
- S. 1097 / H.R. 4570 Interagency Patent Coordination and Improvement Act of 20253 filings
- S. 2062 / H.R. 3955 RAPID Reserve Act3 filings
- S. 2658 Medication Affordability and Patent Integrity Act3 filings
- S. 3788 / H.R. 8269 CLEAR LABELS Act3 filings
- H.R. 6986, 118th To address patent thickets.2 filings
- S. 142, 118th Preserve Access to Affordable Generics and Biosimilars Act2 filings
- S. 150, 118th Affordable Prescriptions for Patients Act of 20232 filings
- S. 2140, 118th Patent Eligibility Restoration Act of 20232 filings
- S. 2220 / H.R. 4370, 118th PREVAIL Act2 filings
- H.R. 7148 Consolidated Appropriations Act, 2026 Broad bill2 filings
- S. 2296 National Defense Authorization Act for Fiscal Year 2026 Broad bill2 filings
- H.R. 1352, 118th Increasing Access to Biosimilars Act of 20231 filing
- H.R. 1980 State Strategic Stockpile Act of 20251 filing
- H.R. 2880, 118th Protecting Patients Against PBM Abuses Act1 filing
- H.R. 3839, 118th To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.1 filing
- H.R. 5461, 118th Ensuring Access to Lower-Cost Medicines for Seniors Act of 20231 filing
- H.R. 6109, 118th PILLS Act1 filing
- H.R. 6992 EB–5 Regional Center Program Advisory Committee Authorization Act1 filing
- H.R. 8339 Drug Origin Transparency Act of 20261 filing
- H.R. 9070, 118th Affordable Prescriptions for Patients Act of 20241 filing
- H.R. 9474, 118th Patent Eligibility Restoration Act of 20241 filing
- S. 1095 Stop STALLING Act1 filing
- S. 1114, 118th Expanding Access to Low-Cost Generics Act of 20231 filing
- S. 2129, 118th Ensuring Access to Lower-Cost Medicines for Seniors Act1 filing
- S. 2305, 118th Biosimilar Red Tape Elimination Act1 filing
- S. 2362 / H.R. 3008, 118th Drug Shortage Prevention Act of 20231 filing
- S. 2780 / H.R. 5429, 118th Medication Affordability and Patent Integrity Act1 filing
- S. 3583, 118th A bill to address patent thickets.1 filing
- S. 3934, 118th On congress.gov1 filing
- S. 4280 SAFE Act1 filing
- S. 5368 / H.R. 10239, 118th End Drug Shortages Act1 filing
- S. 5573, 118th Skinny Labels, Big Savings Act1 filing
- S. 775, 118th Increasing Transparency in Generic Drug Applications Act1 filing
- S. 998 / H.R. 2213 Medical Supply Chain Resiliency Act1 filing
- H.R. 1 An act to provide for reconciliation pursuant to title II of H. Con. Res. 14. Broad bill1 filing
- H.R. 10545, 118th American Relief Act, 2025 Broad bill1 filing
- S. 1071 National Defense Authorization Act for Fiscal Year 2026 Broad bill1 filing
- S. 2226 / H.R. 2670, 118th National Defense Authorization Act for Fiscal Year 2024 Broad bill1 filing
From the filings
“Issues S. 43, Skinny Labels, Big Savings Act.”
“Issues related to manufacturing and pharmaceutical trade.”
Contacted as listed on the filings
- U.S. House
- U.S. Senate
- CMS
- HHS
- USTR
- White House Office
- DOC
- FDA
- NEC
- U.S. Customs & Border Protection
- CBO
- OMB
- 7 more
The House and Senate appear in every quarter; agencies in all 8 quarters.
Every filing since 2015 Pro
Free account See ProSource: Lobbying Disclosure Act filings (LD-2) by Association for Accessible Medicines, Senate Office of Public Records. Filings are due 20 days after each quarter ends.
From FEC filings: direct gifts this PAC reported, net of refunds · How we count
Gave directly to 10 sitting members of Congress in 2025–26.
See every candidate and member Association for Accessible Medicines gave to directly, how much, and how its money splits between the parties.
This part is in Pro. A free account lets you follow up to 3 people and get a weekly email about them; upgrade whenever you need more.
Create a free account See what Pro adds Log in